CANC vs IBRN: Holdings Overlap & Returns
Over the year to Nov 13, 2026, CANC returned +25.2% to IBRN's +19.8%; 0% of their weight is in the same names.
- Return gap
- +5.4 pts1 year to Nov 13, 2026: CANC ahead, total return
- Fee gap
- 0.28 ptsA year: CANC 0.75%, IBRN 0.47%, per filings dated Nov 21, 2025 and Jun 29, 2026
- Overlap
- 0%Share of the two books held in common, holdings dated Nov 12, 2026
- Net flow
- –Needs daily flows for both funds
Compare two other funds
Growth of 100
Drawn from the numbers on this page. Growth of 100, both funds, distributions reinvested
CANC +25.2%, IBRN +19.8%: CANC +5.4 pts ahead, 1 year, Nov 13, 2025 to Nov 13, 2026.
ShareUse this comparison
Cost to trade
Hypothetical. A $10,000 order in IBRN costs about $16.00 one way and $32.00 in and out, at a median spread of 0.32%. The 0.32% spread is IBRN’s 30-day median, from iShares (fund page).
Fees over time
Hypothetical. $10,000 in CANC for 10 years at 0.75% a year costs about $1,228 in fees and lost growth; IBRN at 0.47% would cost $778. Assumes 6% a year before fees, a sample rate, not a forecast.
How each fund moved
23% of CANC's weight is in S&P 500 companies and 77% is outside the index. Holdings as of Nov 12, 2026.
5% of IBRN's weight is in S&P 500 companies and 95% is outside the index. Holdings as of Nov 12, 2026.
Key numbers
IBRN costs 0.28 points a year less; their one-year returns differ by 5.4 points; CANC is far larger, $210m against $8.6m.
Pair scorecard
Open the table
Points (pts) are percentage points.
| Total return, 1 year | +25.2% | +19.8% |
|---|---|---|
| Below its all-time high | 9.2%, high on Aug 25, 2026 | 15.9%, high on Aug 19, 2026 |
| What it tracks | Therapeutics and medical devices | Therapeutics and medical devices |
| Expense ratio | 0.75% | 0.47% |
| Net assets, as of Nov 12, 2026 | $210m | $8.6m |
| Holdings in common | 0% |
The numbers behind it
Net assets on Nov 12, 2026: $210m for Tema Oncology ETF and $8.6m for iShares Neuroscience and Healthcare ETF.
Holdings in common uses holdings dated Nov 12, 2026.
What they share
By the books each fund has filed, CANC and IBRN hold 0% of their money in the same securities at the same weight. Holdings dated Nov 12, 2026.
half
0% in common
Only in CANC
Show all 8 holdings
| GENMAB A/S | 5.82% |
| ELI LILLY & CO | 5.62% |
| REVOLUTION MEDICINES INC | 5.34% |
| MERCK & CO INC | 5.03% |
| BEONE MEDICINES LTD | 4.34% |
| COGENT BIOSCIENCES INC | 4.31% |
| NOVARTIS AG | 4.19% |
| ABBVIE INC | 3.88% |
Only in IBRN
Show all 8 holdings
| BIOGEN | 5.33% |
| NEUROCRINE BIOSCIENCES | 5.09% |
| EDGEWISE THERAPEUTICS | 4.96% |
| Alkermes Public Limited Company | 4.75% |
| ARGENX SE ADR | 4.43% |
| PRAXIS PRECISION MEDICINES | 4.30% |
| PTC THERAPEUTICS | 4.29% |
| AXOGEN | 4.28% |
Side by side
Open the table
| Fund | Tema Oncology ETF · Holds 55 stocks in therapeutics and medical devices, 23% of its weight in S&P 500 companies | iShares Neuroscience and Healthcare ETF · Holds 67 stocks in therapeutics and medical devices, 5% of its weight in S&P 500 companies |
| Issuer | Tema | iShares |
| Theme | Therapeutics and medical devices | Therapeutics and medical devices |
| In the S&P 500 | 22.8% | 5.3% |
| Active share vs the S&P 500 | 95.7% | 100.0% |
| In the Nasdaq-100 | 3.1% | 0.0% |
| Holdings | 55 | 67 |
| Top ten, share of the fund | 45.5% | 45.2% |
| Expense ratio | 0.75% | 0.47% |
| Fee for the differing part | 0.78% | 0.47% |
| Total return, 1 year | +25.2% | +19.8% |
| vs its benchmark | not measured | not measured |
| Below its high | −9.2% | −15.9% |
| Net assets, as of Nov 12, 2026 | $210m | $8.6m |
As of Nov 13, 2026. Source: ETFIQ.
Window by window
Open the table
| 3 months | −3.8% | −12.6% |
|---|---|---|
| 6 months | +10.7% | −1.7% |
| 1 year | +25.2% | +19.8% |
| 3 years | +85.9% | +67.5% |
| Since launch (Not the same days: CANC Aug 2023 · IBRN Aug 2022) | +69.4% | +41.2% |
About CANC
By weight, 23% of CANC's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 96%. The top ten holdings are 46% of the fund across 55 positions, as published by its issuer for Nov 12, 2026.
More
Over the year to Nov 13, 2026 the fund returned +25.2% with distributions reinvested. It sits 9.2% below its all-time high of Aug 25, 2026.
About IBRN
By weight, 5% of IBRN's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 100%. The top ten holdings are 45% of the fund across 67 positions, as published by its issuer for Nov 12, 2026.
More
Over the year to Nov 13, 2026 the fund returned +19.8% with distributions reinvested. It sits 15.9% below its all-time high of Aug 19, 2026.
0% of the two portfolios are the same securities at the same weight.
Questions people ask
Do CANC and IBRN hold the same stocks?
By their latest filings, 0% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.
Other comparisons
Sources
More
Links are sources, not endorsements. A comparison is not a recommendation.
Copy and cite
Cite this pageCitation, APA and Markdown
ETFIQ, CANC against IBRN, data as of Nov 13, 2026. https://etfiq.com/compare/themes/canc-vs-ibrn
ETFIQ. (Nov 13, 2026). CANC against IBRN. Retrieved from https://etfiq.com/compare/themes/canc-vs-ibrn
[CANC against IBRN (ETFIQ, Nov 13, 2026)](https://etfiq.com/compare/themes/canc-vs-ibrn)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.